Ligand Pharmaceuticals (LGND) Liabilities and Shareholders Equity (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 69.21% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $5.5 billion (up 50.42% YoY), and the FY2025 full-year result was $1.6 billion, up 65.71% from the prior year.
• Liabilities and Shareholders Equity fell to $1.5 billion in Q1 2026, from $1.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.6 billion in Q4 2025 to a low of $758.1 million in Q2 2023.
• A 5-year average of $1.0 billion and a median of $941.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity plunged 41.22% in 2022 and surged 69.21% in 2026, its largest moves.
• Tracing LGND's Liabilities and Shareholders Equity over 5 years: stood at $762.7 million in 2022, then rose by 3.22% to $787.2 million in 2023, then gained by 19.63% to $941.8 million in 2024, then jumped by 65.71% to $1.6 billion in 2025, then decreased by 1.83% to $1.5 billion in 2026.
• Business Quant data shows LGND's Liabilities and Shareholders Equity at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.5 billion in Q3 2025.